TC Medical's 1H 2020 Revenue Totals CNY 738 Mn, Down 12.87% YoY
TC Medical released its financial report for 1H 2020, showing that the company earned revenue of CNY 738 million, down 12.87% year-on-year; net profit of CNY 145 million, down 30.22% year-on-year.
This text is a result of machine translation.
Related companies：
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
In-depth
Healthcare
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Consumer Discretionary, IndustrialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Real Estate, Consumer Discretionary, IndustrialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Oct 19, 2021 06:56 AM
· Financials
The investment banking business was strictly supervised, and seven securities companies received fines
Healthcare
AI-driven Biotech Galixir Nominates Preclinical Candidate in Treating Autoimmune Disease
Founded in 2019, Galixir named a Preclinical Candidate (PCC) for the treatment of Autoimmune Disease (AID) which was screened out of around 80 compounds via its proprietary platform, Pyxir®, making it another top-ranking China-based AI-driven drug discovery company.
Jun 21, 2022 01:44 PM
Briefing Oct 17, 2021 06:26 PM
· Healthcare
The first batch of "Mao" concept achievements were released, with a year-on-year growth of more than 50%
Briefing Oct 15, 2021 06:25 PM
· Healthcare
Wantai biology: it is proposed to raise no more than 3.5 billion yuan for the phase II expansion project of nine price cervical cancer vaccine
In-depth
Healthcare
Where Will AI Take Drug Discovery in China to?
The development of drug discovery in China is relatively slower than in many other countries but China’s pharma market size is among the top three worldwide. Deeper exploration of drug discovery is much needed in China. AI can make a machine execute tasks like a human or even better than humans. With many emerging AI-powered drug discovery companies in China, can AI help China beat the pioneers in drug discovery at their own game?
Jun 21, 2022 01:19 PM
Briefing Sep 17, 2021 11:58 AM
· Technology
Amazon: the policy is consistent all over the world, and the title is not for Chinese businesses
Briefing Jul 20, 2021 01:18 AM
· Consumer Staples
Zhang Kun's four funds decreased their positions in the second quarter by allocating Wuliangye to Guizhou Maotai
See more
Read next
In-depth
In-depth
In-depth
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.